Pinpoint Genomics makes Pinpoint Dx Lung Assay available to clinicians, patients

Pinpoint Genomics, Inc.  announced the publication of key data relating to its Pinpoint Dx Lung™ Assay in the journal The Lancet, and the availability of its Pinpoint Dx Lung™ Assay to clinicians and patients exclusively through the company's laboratory in Mountain View, CA.

The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF), as well as the results of the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer. The two validation studies, conducted by the Kaiser Permanente Division of Research and the China Clinical Trials Consortium, involved 433 patients from northern California and 1,006 patients from several leading cancer centers in China, respectively.

The Pinpoint Dx Lung™ assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint's Clinical Laboratory Improvement Amendment-certified laboratory.

SOURCE Pinpoint Genomics, Inc.